Skip to content

Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05197413
Enrollment
35
Registered
2022-01-19
Start date
2021-09-01
Completion date
2021-12-31
Last updated
2022-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, IBS - Irritable Bowel Syndrome

Brief summary

This is an open-label observational crossover trial to study the efficacy of a commercial dietary supplement and its effect on common symptoms of IBS (such as bloating, gas, heartburn, and other symptoms).

Detailed description

It is hypothesized that the dietary supplement marketed as Arrae Bloat will improve subjective wellbeing in trial participants. It is further hypothesized that a second dietary supplement marketed as Arrae Calm will support the effects of Arrae Bloat, while reducing stress, anxiety and panic and promoting restful sleep and easing tension in the body, which has previously been reported in customer feedback studies.

Interventions

DIETARY_SUPPLEMENTArrae bloat supplement

The supplement contains organic dandelion root extract, organic lemon balm herb top extract, organic peppermint leaf extract, organic bromelain, organic slippery elm inner bark extract. The capsule itself is made of cellulose, which is not a main active ingredient.

Sponsors

Citruslabs
CollaboratorINDUSTRY
Arrae
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Female over 18 years old * Self-reported (undiagnosed) IBS symptoms, such as self-reported abdominal pain, gas production and bloating after meals, heartburn after meals * Must be in good health (don't report any medical conditions asked in the screening questionnaire) * Following a stable, consistent diet regimen * Agree to refrain from any lifestyle changes that may affect their GI tract and IBS symptoms for the duration of the study * May have self-reported sleep issues * May have self-reported mild anxiety/depression * May have self-reported occasional panic attacks

Exclusion criteria

* Prior prescriptions for IBS * Current IBS treatment (e.g. proton pump inhibitors, laxatives) * Follow an extreme diet intervention * Experienced severe weight loss in the past 3 months prior to study participation * Antibiotic usage within 3 months prior of study participation * Usage any medication or herbal remedies which can affect the GI tract * Food intolerances/allergies * Pineapple sensitivity/allergy * Taking cortisol lowering prescription medication * Has any of the following medical conditions: History of GI tract cancers Celiac disease / gluten intolerance GI bleeding Rectal bleeding Heme-positive stool Iron-deficiency anemia Systemic signs of infection Insomnia Moderate to severe depression/anxiety Moderate to severe panic attacks \- Females that are pregnant, want to become pregnant for the duration of the study, or who are breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Reduction in IBS symptoms (bloating, heartburn and gas)4 weeksSurvey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in IBS symptoms between baseline and study intervention period.
Reduction in anxiety symptoms8 weeksSurvey-based assessment (0-5 scale with 0 being the lowest possible score and 5 being the highest) of changes in anxiety symptoms between baseline and study intervention period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026